Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
09/19/2024 | Press release | Distributed by Public on 09/19/2024 15:47
Please select the service you want to use:
Smartlinks | Keysight Technologies Inc. | News | Securities Issuers | Precision, Testing and Measuring Equipment Manufacturers | London Stock Exchange (LSE) | New York Stock Exchange (NYSE) | Frankfurt Stock Exchange | Sao Paulo Stock Exchange (B3) | Vienna Stock Exchange (ATX) | Berlin Stock Exchange | Dusseldorf Stock Exchange | Stuttgart Stock Exchange | Bolsa Mexicana de Valores (BMV) | Moscow Exchange (MOEX) | BX Swiss | Tradegate Exchange | XETRA | NYSE American | NYSE ARCA Equities | Cboe BZX Exchange | Cboe Off Exchange | Cboe BYX Exchange | Cboe EDGA Exchange | Cboe EDGX Exchange | NYSE National | FINRA Alternative Display Facility (ADF) | Investors Exchange (IEX) | Bolsa Institucional de Valores (BIVA) | Hannover Stock Exchange | Nasdaq BX | Nasdaq Intermarket | Nasdaq PSX | NYSE Chicago
Back
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact